Literature DB >> 22151225

Peripheral nerve field stimulation: is age an indicator of outcome?

Paul Verrills1, Bruce Mitchell, David Vivian, Chantelle Sinclair.   

Abstract

Objective.  This study aims to assess peripheral nerve field stimulation as a treatment option for chronic pain and test for indicators of outcome. Materials and Methods.  We reviewed all patients permanently implanted with peripheral nerve field stimulators over the past 24 months. A questionnaire was used to assess outcomes. Results.  Twenty-seven questionnaires were sent out and 23/27 responded. A significant average decrease of 4.02 visual analog scale points was observed. The average pain decrease for the low back was 3.77 points and 5.9 for occipital implants. An age effect was detected; younger patients (<60 years) reported an average pain relief of 4.79 points while older patients (>61 years) reported an average pain relief decrement of only 2.83 points. Most patients reported decreases in analgesic use after treatment. Pain relief was significantly and highly correlated with reduced analgesic intake and patient satisfaction. Conclusion.  Peripheral nerve field stimulation is a safe, reversible, and effective treatment option for patients with chronic pain, particularly those under 60 years.
© 2009 International Neuromodulation Society.

Entities:  

Year:  2009        PMID: 22151225     DOI: 10.1111/j.1525-1403.2009.00190.x

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  2 in total

1.  Intractable sacroiliac joint pain treated with peripheral nerve field stimulation.

Authors:  Shushovan Chakrabortty; Sanjeev Kumar; Deepak Gupta; Sruthi Rudraraju
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jul-Sep

2.  Assessing the effectiveness and cost effectiveness of subcutaneous nerve stimulation in patients with predominant back pain due to failed back surgery syndrome (SubQStim study): study protocol for a multicenter randomized controlled trial.

Authors:  Sam Eldabe; Michael Kern; Wilco Peul; Colin Green; Kristi Winterfeldt; Rod S Taylor
Journal:  Trials       Date:  2013-06-25       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.